Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Over the last 12 months, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $125,606 worth of Checkpoint Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $250,177 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $127,000 was made by ROSENWALD LINDSAY A MD (director) on 2019‑11‑20.
2024-06-26 | Sale | CEO, President and Director | 24,610 0.0674% | $2.05 | $50,451 | +17.87% | ||
2024-06-26 | Sale | Chief Financial Officer | 13,038 0.0359% | $2.06 | $26,858 | +17.87% | ||
2024-02-28 | Sale | CEO, President and Director | 5,894 0.0247% | $2.06 | $12,142 | +5.85% | ||
2024-02-28 | Sale | Chief Financial Officer | 2,035 0.0086% | $2.07 | $4,212 | +5.85% | ||
2024-02-01 | Sale | CEO, President and Director | 11,900 0.0552% | $2.01 | $23,919 | +6.63% | ||
2024-02-01 | Sale | Chief Financial Officer | 4,115 0.0185% | $1.95 | $8,024 | +6.63% | ||
2023-03-02 | Sale | CEO, President and Director | 5,483 <0.0001% | $5.00 | $27,415 | -55.93% | ||
2023-03-02 | Sale | Chief Financial Officer | 3,591 <0.0001% | $5.00 | $17,955 | -55.93% | ||
2023-02-27 | Sale | CEO, President and Director | 5,548 <0.0001% | $4.65 | $25,798 | -51.41% | ||
2023-02-27 | Sale | Chief Financial Officer | 1,914 <0.0001% | $4.66 | $8,919 | -51.41% | ||
2023-02-01 | Sale | CEO, President and Director | 10,261 <0.0001% | $4.77 | $48,945 | -50.47% | ||
2023-02-01 | Sale | Chief Financial Officer | 3,154 <0.0001% | $4.79 | $15,108 | -50.47% | ||
2023-01-10 | Sale | CEO, President and Director | 3,817 <0.0001% | $6.75 | $25,761 | -62.55% | ||
2023-01-10 | Sale | Chief Financial Officer | 1,858 <0.0001% | $6.75 | $12,540 | -62.55% | ||
2022-06-17 | Sale | CEO, President and Director | 15,000 0.0183% | $1.11 | $16,650 | -44.09% | ||
2022-04-13 | Sale | CEO, President and Director | 21,258 0.024% | $1.51 | $32,100 | -35.33% | ||
2022-04-05 | Sale | CEO, President and Director | 14,030 0.0164% | $1.77 | $24,833 | -42.20% | ||
2022-04-04 | Sale | CEO, President and Director | 86,353 0.0998% | $1.79 | $154,572 | -42.94% | ||
2022-03-10 | Sale | Chief Financial Officer | 38,197 0.0447% | $1.89 | $72,307 | -43.68% | ||
2022-02-01 | Sale | Chief Financial Officer | 37,063 0.0429% | $2.51 | $92,954 | -55.69% |
Oliviero James F III | CEO, President and Director | 1977170 4.1078% | $3.97 | 0 | 13 | |
GRAY WILLIAM GARRETT | Chief Financial Officer | 672186 1.3965% | $3.97 | 0 | 12 | |
ROSENWALD LINDSAY A MD | director | 237890 0.4942% | $3.97 | 4 | 0 | +32.45% |
Armistice Capital Llc | $5.57M | 7.36 | 2.72M | +11.95% | +$594,500.00 | 0.02 | |
The Vanguard Group | $1.88M | 2.49 | 917,894 | +67.41% | +$757,651.42 | <0.0001 | |
Renaissance Technologies | $556,000.00 | 0.74 | 271,217 | +63.65% | +$216,248.30 | <0.01 | |
Geode Capital Management | $407,028.00 | 0.54 | 198,501 | +14.18% | +$50,559.39 | <0.0001 | |
BlackRock | $339,160.00 | 0.45 | 165,444 | -0.64% | -$2,197.60 | <0.0001 | |
Advisor Group Holdings Inc | $277,112.00 | 0.37 | 135,177 | -17.21% | -$57,617.12 | <0.01 | |
D. E. Shaw & Co. | $222,655.00 | 0.29 | 108,612 | -22.72% | -$65,464.82 | <0.0001 | |
Legacy Wealth Asset Management Llc | $174,250.00 | 0.23 | 85,000 | 0% | +$0 | 0.05 | |
Envestnet Asset Management Inc | $157,116.00 | 0.21 | 76,642 | +77.49% | +$68,597.06 | <0.0001 | |
Millennium Management LLC | $130,038.00 | 0.17 | 63,433 | +432.11% | +$105,599.88 | <0.0001 | |
State Street | $124,074.00 | 0.16 | 60,524 | 0% | +$0 | <0.0001 | |
Royal Bank of Canada | $125,000.00 | 0.16 | 60,476 | -0.31% | -$390.65 | <0.0001 | |
Park Avenue Securities Llc | $123,000.00 | 0.16 | 59,915 | -0.03% | -$34.90 | <0.01 | |
Rsm Us Wealth Management Llc | $118,740.00 | 0.16 | 57,922 | +200.89% | +$79,277.53 | <0.01 | |
Susquehanna International Group | $115,671.00 | 0.15 | 56,425 | -40.64% | -$79,205.68 | <0.0001 | |
Wealth Enhancement Advisory Services LLC | $102,500.00 | 0.14 | 50,000 | -41.18% | -$71,750.00 | <0.0001 | |
National Asset Management Inc | $83,555.00 | 0.13 | 49,150 | -69.91% | -$194,140.00 | <0.01 | |
Northern Trust | $88,863.00 | 0.12 | 43,348 | +9.34% | +$7,593.17 | <0.0001 | |
Lindbrook Capital LLC | $61,500.00 | 0.08 | 30,000 | New | +$61,500.00 | 0.01 | |
Magnus Financial Group LLC | $61,500.00 | 0.08 | 30,000 | +25% | +$12,300.00 | 0.01 | |
CETERA INVESTMENT ADVISERS LLC | $49,932.00 | 0.07 | 24,357 | +69.77% | +$20,520.56 | <0.0001 | |
Emfo Llc | $32,216.00 | 0.04 | 15,715 | 0% | +$0 | 0.03 | |
Ironwood Investment Management Llc | $26,012.00 | 0.03 | 12,689 | +8.61% | +$2,062.26 | 0.01 | |
Cetera Advisors LLC | $25,350.00 | 0.03 | 12,366 | New | +$25,350.00 | <0.0001 | |
Apollon Wealth Management, LLC | $23,645.00 | 0.03 | 11,534 | New | +$23,645.00 | <0.01 | |
Cibc Asset Management Inc | $23,134.00 | 0.03 | 11,285 | 0% | +$0 | <0.0001 | |
Morgan Stanley | $21,853.00 | 0.03 | 10,659 | +31.61% | +$5,248.49 | <0.0001 | |
Raymond James Financial Services Advisors Inc | $21,720.00 | 0.03 | 10,595 | New | +$21,720.00 | <0.0001 | |
Tower Research Capital | $14,813.00 | 0.02 | 7,226 | -35.33% | -$8,093.24 | <0.0001 | |
Citadel Advisors LLC | $13,719.00 | 0.02 | 6,692 | New | +$13,719.00 | <0.0001 | |
Wells Fargo | $6,476.00 | 0.01 | 3,159 | -81.57% | -$28,657.17 | <0.0001 | |
UBS | $3,077.00 | <0.01 | 1,501 | -1.51% | -$47.15 | <0.0001 | |
Householder Group Estate Retirement Specialist Llc | $410.00 | <0.01 | 200 | -33.33% | -$205.00 | <0.0001 | |
Tsfg Llc | $1,000.00 | <0.01 | 300 | 0% | +$0 | <0.0001 | |
JPMorgan Chase | $2.00 | <0.01 | 1 | 0% | +$0 | <0.0001 | |
VisionPoint Advisory Group | $205.00 | <0.01 | 100 | New | +$205.00 | <0.0001 | |
Fidelity Investments | $308.00 | <0.01 | 150 | New | +$308.00 | <0.0001 |